Your session is about to expire
← Back to Search
Dato-DXd + Durvalumab for Breast Cancer
Study Summary
This trial tests the effectiveness and safety of new treatments for TNBC and hormone receptor-low/HER2-negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does the FDA recognize Dato-DXd in combination with durvalumab as a viable treatment?
"Our team has assigned a score of 3 to the safety profile of Dato-DXd plus durvalumab, due to existing evidence from Phase 3 trials displaying both efficacy and repeated guarantee of safety."
How many areas are hosting this clinical exploration?
"Patients can join this clinical trial at 128 different sites, located in Jonesboro, Rogers and Los Angeles as well as 125 other cities. To reduce the burden of travel it is suggested that you choose a clinic near to your own location."
Are there still opportunities available to participate in this research initiative?
"According to the information posted on clinicaltrials.gov, this trial has ceased recruitment and is no longer seeking participants. It was initially listed on November 15th 2023 and last updated October 31st of that same year. However, those interested may find solace in knowing that there are over 2700 other medical studies actively enrolling patients at this time."
What ambitious goals does this research endeavor aim to accomplish?
"The central aim of this trial is to assess Event-free Survival (EFS) in the experimental and control arms over a specified timeline. Other secondary outcomes that will be evaluated include Distant Disease-Free Survival (DDFS), Participant-reported Breast & Arm Symptoms, and Physical Function Scores measured by the PROMIS Short Form 8c. Data analysis will encompass all randomised participants regardless of whether they withdraw or receive alternative therapy. Hazard Ratios for DDFS as well as mean between arm differences in other metrics are included among the measures of interest."
Share this study with friends
Copy Link
Messenger